| Primary |
| Acromegaly |
58.9% |
| Product Used For Unknown Indication |
10.2% |
| Neuroendocrine Tumour |
8.8% |
| Carcinoid Tumour |
4.2% |
| Carcinoid Syndrome |
3.1% |
| Drug Use For Unknown Indication |
2.5% |
| Diarrhoea |
1.7% |
| Neuroendocrine Carcinoma Of The Skin |
1.1% |
| Pancreatic Neuroendocrine Tumour |
1.1% |
| Post Gastric Surgery Syndrome |
1.1% |
| Body Height Above Normal |
0.8% |
| Brain Neoplasm |
0.8% |
| Gastrointestinal Disorder |
0.8% |
| Insulinoma |
0.8% |
| Pancreatic Carcinoma |
0.8% |
| Abdominal Pain Upper |
0.6% |
| Body Height Increased |
0.6% |
| Fistula Repair |
0.6% |
| Nasopharyngitis |
0.6% |
| Obesity |
0.6% |
|
| Vomiting |
10.7% |
| Death |
9.9% |
| Nausea |
8.3% |
| Diarrhoea |
6.6% |
| Injection Site Nodule |
5.8% |
| Weight Decreased |
5.8% |
| Cytolytic Hepatitis |
5.0% |
| Headache |
5.0% |
| Malaise |
4.1% |
| Off Label Use |
4.1% |
| Pancreatitis |
4.1% |
| Suicidal Ideation |
4.1% |
| Condition Aggravated |
3.3% |
| Fatigue |
3.3% |
| General Physical Health Deterioration |
3.3% |
| Injection Site Pain |
3.3% |
| Loss Of Consciousness |
3.3% |
| Renal Impairment |
3.3% |
| Urinary Tract Infection |
3.3% |
| Weight Increased |
3.3% |
|
| Secondary |
| Acromegaly |
40.0% |
| Product Used For Unknown Indication |
11.9% |
| Carcinoid Syndrome |
8.9% |
| Gastrointestinal Disorder |
8.1% |
| Metastases To Liver |
3.7% |
| Neuroendocrine Tumour |
3.7% |
| Pancreatic Carcinoma |
3.7% |
| Carcinoid Tumour |
3.0% |
| Neuroendocrine Carcinoma |
3.0% |
| Pancreatic Neuroendocrine Tumour |
3.0% |
| Post Procedural Diarrhoea |
3.0% |
| Insulinoma |
1.5% |
| Intestinal Resection |
1.5% |
| Diarrhoea |
0.7% |
| Hypogonadism |
0.7% |
| Hypothyroidism |
0.7% |
| Malignant Peritoneal Neoplasm |
0.7% |
| Migraine |
0.7% |
| Mineral Supplementation |
0.7% |
| Nocturia |
0.7% |
|
| Weight Decreased |
10.1% |
| Dehydration |
8.7% |
| Intestinal Functional Disorder |
8.7% |
| Nausea |
8.7% |
| Off Label Use |
8.7% |
| Muscle Spasms |
7.2% |
| Cytolytic Hepatitis |
5.8% |
| Metastases To Lung |
5.8% |
| Neuroendocrine Tumour |
4.3% |
| Spinal Fracture |
4.3% |
| Vomiting |
4.3% |
| Blood Sodium Decreased |
2.9% |
| Bone Pain |
2.9% |
| Death |
2.9% |
| Flatulence |
2.9% |
| Hypertension |
2.9% |
| Malaise |
2.9% |
| Mass |
2.9% |
| Abdominal Pain Upper |
1.4% |
| Alopecia |
1.4% |
|
| Concomitant |
| Acromegaly |
14.0% |
| Product Used For Unknown Indication |
12.3% |
| Pain |
10.5% |
| Antibiotic Therapy |
7.0% |
| Neuroendocrine Tumour |
7.0% |
| Hypertension |
5.3% |
| Ovarian Cancer |
5.3% |
| Crohn's Disease |
3.5% |
| Ex-tobacco User |
3.5% |
| Gastrointestinal Pain |
3.5% |
| Hyperchlorhydria |
3.5% |
| Hypothalamo-pituitary Disorder |
3.5% |
| Muscle Relaxant Therapy |
3.5% |
| Parenteral Nutrition |
3.5% |
| Thrombosis Prophylaxis |
3.5% |
| Vitamin Supplementation |
3.5% |
| Blood Growth Hormone Abnormal |
1.8% |
| Gigantism |
1.8% |
| Headache |
1.8% |
| High Density Lipoprotein Decreased |
1.8% |
|
| Biliary Colic |
10.5% |
| Pruritus |
10.5% |
| Breast Pain |
5.3% |
| Cardiac Arrest |
5.3% |
| Chronic Obstructive Pulmonary Disease |
5.3% |
| Death |
5.3% |
| Diarrhoea |
5.3% |
| Enterocutaneous Fistula |
5.3% |
| Influenza Like Illness |
5.3% |
| Insulin-like Growth Factor Increased |
5.3% |
| Metabolic Acidosis |
5.3% |
| Muscular Weakness |
5.3% |
| Peritonitis |
5.3% |
| Photosensitivity Reaction |
5.3% |
| Respiratory Failure |
5.3% |
| Staphylococcal Sepsis |
5.3% |
| Weight Increased |
5.3% |
|
